Recent advances in primary Sjogren's syndrome
Open Access
- 17 June 2016
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 5, 1412
- https://doi.org/10.12688/f1000research.8352.1
Abstract
Primary Sjögren’s syndrome, a chronic inflammatory process, is among the most commonly occurring rheumatologic diseases. The clinical hallmark of this disease is exocrine gland dysfunction, resulting predominately in dry eyes and dry mouth. However, the disease often extends beyond the exocrine glands to seriously affect other organs systems, such as the lungs, kidneys, and nervous system. Moreover, patients with primary Sjögren’s syndrome develop non-Hodgkin’s B cell lymphoma at a substantially higher rate than the general population. New research has improved our understanding of disease mechanisms, with notable advances in our knowledge about the genetic susceptibility of disease, the molecular details of the chronic inflammatory response in the salivary glands, and the complex role of the type 1 interferon pathway. The pipeline of drugs under development for the treatment of primary Sjögren’s syndrome is enriched with novel biologics and small molecular entities targeting the pathogenic process. Herein, we summarize the latest advances in elucidating the pathogenesis of primary Sjögren’s syndrome and highlight new drugs in clinical development aiming to reverse the glandular dysfunction and favorably impact the systemic features of this disease.Keywords
This publication has 55 references indexed in Scilit:
- Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseasesProceedings of the National Academy of Sciences, 2012
- Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Sjögren syndrome: Advances in the pathogenesis from animal modelsJournal of Autoimmunity, 2009
- The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndromeArthritis & Rheumatism, 2009
- Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren syndrome in salivary glands of non-obese diabetic miceArthritis Research & Therapy, 2009
- Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor and systemic immune activationAnnals Of The Rheumatic Diseases, 2008
- Inhibition of the lymphotoxin pathway as a therapy for autoimmune diseaseImmunological Reviews, 2008
- Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR‐ and type‐I IFN‐dependent and ‐independent pathwaysEuropean Journal of Immunology, 2008
- Association of an IRF5 gene functional polymorphism with Sjögren's syndromeArthritis & Rheumatism, 2007
- Induction of interferon‐α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgGArthritis & Rheumatism, 2004